Investigational Agents and Ongoing Clinical Trials in Advanced RAI-R-DTC

In an interview with Targeted Oncology, Marcia S. Brose, MD, PhD, FASCO discussed the impact of selpercatinib in thyroid cancer, and what to expect from the drug in the future.

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

According to Marcia Brose, MD, PhD, FASCO, interim findings from the phase 3 LIBRETTO-531 trial confirms the benefit of selpercatinib in patients with advanced, RET-mutant medullary thyroid cancer.

Investigators have shared final results from the first prospective study of a BRAK/MEK inhibitor combination in patients with advanced rare cancer, including anaplastic thyroid cancer.

In an interview with Targeted Oncology, Warren C. Swegal, MD, takes a deep dive into the radioactive iodine-refectory differentiated thyroid cancer treatment armamentarium, and predicts the role of key agents in the near future.

Though scientific advances have been encouraging in the thyroid cancer space, there is much more work to be done to figure out exactly how to tailor the right therapy, or combination of therapies, for individual patients.